IDO1 and neoplasm: Moreover, tumor formation of CRISPR Ido1-KO mice (LLC-CRSG2) was significantly slower than control LLC-CR, and treatment with AT-0174 further suppressed LLC-CRSG2 tumor growth and weight (Fig. 4E).